Abivax announces first patient enrolled in enhance-cd, the phase 2b trial of obefazimod in crohn's disease

Abivax announces first patient enrolled in enhance-cd, the phase 2b trial of obefazimod in crohn's disease paris, france, october 3, 2024 – 10:00 p.m. cest – abivax sa (euronext paris: fr0012333284 – abvx; nasdaq: abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the first patient was enrolled in its phase 2b enhance-cd (nct06456593) trial evaluating obefazimod in patients with crohn's disease (cd).
ABVX Ratings Summary
ABVX Quant Ranking